Skip to main content
SpringerLink
Log in

Safety Profiles of the Angiotensin-Converting Enzyme Inhibitors

  • Section 3: Quality of Life
  • Published:
Drugs Aims and scope Submit manuscript

Summary

This review will discuss the safety profiles of the angiotensin-converting enzyme (ACE) inhibitors captopril, enalapril and lisinopril in patients with hypertension. In general, the safety profiles of ACE inhibitors compare favourably with those of other agents used for the treatment of hypertension. Adverse effects are not common when ACE inhibitors are used at the currently recommended doses. The adverse experiences that do occur with ACE inhibitors can be divided into 3 categories. Hypotension, hyperkalaemia and renal impairment are related directly to the blockade of the angiotensin-converting enzyme. Attention to the clinical condition, including concomitant therapy, reduces the risk of these adverse effects of ACE inhibition. Other adverse effects such as cough and angioedema also occur with all ACE inhibitors. The mechanisms are poorly understood, making it difficult to predict in which patients they will occur. Adverse effects such as rash, dysgeusia, neutropenia and proteinuria, which were reported relatively frequently in the early experience with captopril, are reported less frequently with lower doses of captopril and do not appear to be a problem with other ACE inhibitors such as enalapril and lisinopril.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bolzano K, Bernai AR, Bernardes H, Calderon JL, Debruyn J, et al: The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): 43–47, 1987

    Article  Google Scholar 

  • Boner G, Morduchowicz G, Rotenberg Z, Weinberger I, Shohat J, et al. Deterioration in renal function in patients with chronic renal failure after treatment with captopril. Israel Journal of Medicine Science 21: 892–894, 1985

    CAS  Google Scholar 

  • Burnakis TG, Mioduch HR. Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia. Archives of Internal Medicine 144: 2371–2372, 1984

    Article  PubMed  CAS  Google Scholar 

  • Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton JJ, et al. Severe hypotension after first dose of enalapril in heart failure. British Medical Journal 291: 1309–1312, 1985

    Article  PubMed  CAS  Google Scholar 

  • Coulter DM, Edwards IR. Cough associated with captopril and enalapril. British Medical Journal 294: 1521–1526, 1987

    Article  PubMed  CAS  Google Scholar 

  • Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, et al. The effects of antihypertensive therajpy on the quality of life. New England Journal of Medicine 314: 1657–1664, 1986

    Article  PubMed  CAS  Google Scholar 

  • Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncloa F. Enalapril worldwide experience. American Journal of Medicine 77:23–35, 1984

    Article  PubMed  CAS  Google Scholar 

  • DiBiarieo R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors. Medical Toxicology 1: 122–141, 1986

    Google Scholar 

  • FDA-approved package insert. Capoten-R tablets; captopril tablets, June 1985

  • FDA-approved package insert. Vasotec-R tablets; enalapril maleate, December 1985

  • Fernandez PG, Kim BJC, Galway AB. An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension. Pharmatherapeutica 3: 505–514, 1984

    PubMed  CAS  Google Scholar 

  • Frohlich ED, Cooper RA, Lewis EJ. Review of the overall experience of captopril in hypertension. Archives of Internal Medicine 144: 1441–1444, 1984

    Article  PubMed  CAS  Google Scholar 

  • Gluck-Z, Beretta-Pieeoli C, Reubi FC. Long term effects of captopril on renal function in hypertensive patients. European Journal of Clinical Pharmacology 26: 315–323, 1984

    Article  PubMed  Google Scholar 

  • Hallwright GP, Maling TBJ, Town GI. Enalapril and cough. National Medical Journal 99: 66–67, 1986

    CAS  Google Scholar 

  • Havelka J, Vetter H, Studer A, Greminger P, Lüscher T, et al. Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. American Journal of Cardiology 49: 1467–1474, 1982

    Article  PubMed  CAS  Google Scholar 

  • Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, et al. Factors related to first dose hypotensive effect of captopril: prediction and treatment. British Medical Journal 286: 823–834, 1983

    Article  Google Scholar 

  • Hollenberg NK. Medical therapy of renovascular hypertension: Efficacy and safety of captopril in 269 patients. Cardiovascular Reviews & Reports 4: 852–856, 1983

    Google Scholar 

  • Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. New England Journal of Medicine 308: 373–376, 1983

    Article  PubMed  CAS  Google Scholar 

  • Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. American Journal of Medicine 81 (Suppl. 4C): 46–50, 1986

    Article  PubMed  CAS  Google Scholar 

  • Jaffe IA. The adverse effects profile of sulfhydryl compounds in man. American Journal of Medicine 80: 471–476, 1986

    Article  PubMed  CAS  Google Scholar 

  • Jenkins AC, Dreslinski GR, Tadros SS, Groel JT, Fand R, et al. Captopril in hypertension: seven years later. Journal of Cardiovascular Pharmacology 7: S96–S101, 1985

    Article  PubMed  Google Scholar 

  • Kaplan AP. Drug induced skin disease. Journal of Allergy and Clinical Immunology 73: 573–597, 1984

    Article  Google Scholar 

  • MacGregor GA, Markandir ND, Bayliss J, Roulston JE, Squires M. Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK412): evidence for a role of renin system in normotensive subjects. British Medical Journal 283: 401–403, 1981

    Article  PubMed  CAS  Google Scholar 

  • Moncloa F, Sromovsky JA, Walker JF, Davies RO. Enalapril in hypertension and congestive heart failure. Drugs 30 (Suppl. 1): 82–89, 1985

    Article  PubMed  Google Scholar 

  • Morlin C, Baglivo H, Boeijinga JK, Breckenridge AM, Clement D, et al. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): 48–52, 1987

    Article  Google Scholar 

  • Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. British Medical Journal 288: 844–845, 1984

    Article  PubMed  CAS  Google Scholar 

  • Nicholls MG. Side effects and metabolic effects of convertingenzyme inhibitors. Clinical and Experimental Hypertension Theory and Practice A9: 653–664, 1987

    Article  Google Scholar 

  • Nicholls MG, Gilchrist NL. Sulindac and cough produced by converting enzyme inhibitors. Lancet 1:8537, 1987

    Google Scholar 

  • Nies AS. Adverse reactions and interactions limiting the use of antihypertensive drugs. American Journal of Medicine 58: 495–503, 1975

    Article  PubMed  CAS  Google Scholar 

  • Pierpont GL, Francis GS, Conn JN. Effect of captopril on renal function in patients with congestive heart failure. British Heart Journal 46: 522–527, 1981

    Article  PubMed  CAS  Google Scholar 

  • Pool JL, Gennari J, Goldstein R, Kochar MS, Lewin AJ, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): S36–S42, 1987

    Article  PubMed  Google Scholar 

  • Rimmer JM, Horn JF, Gennari J. Hyperkalemia is a complication of drug therapy. Archives of Internal Medicine 147: 867–869, 1987

    Article  PubMed  CAS  Google Scholar 

  • Robertson JIS. Overview: renal disease and ace inhibition: II. Kidney International 31: 130–131, 1987

    Article  Google Scholar 

  • Rush JE, Merrill DD. The safety and tolerability of lisinopril in clinical trials. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): 99–107, 1987

    Article  Google Scholar 

  • Smith WM, Kulaga SF, Moncloa F, Pingeon R, Walker JF. Overall tolerance and safety of enalapril. Journal of Hypertension 2 (Suppl. 2): 113–117, 1984

    CAS  Google Scholar 

  • Stumpe KO, Kolloch R, Overlack A. Captopril und Enalapril Therapeutische Effektivität und Sicherheit. Therapiewoche 34: 3290–3298, 1984

    Google Scholar 

  • Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. American Journal of Medicine 73: 719–725, 1982

    Article  PubMed  CAS  Google Scholar 

  • Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 31:198–248, 1986

    Article  PubMed  CAS  Google Scholar 

  • Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Archives of Internal Medicine 144: 1947–1953, 1984

    Article  Google Scholar 

  • Warren SE, O’Connor DT. Hyperkalemia resulting from captopril administration. Journal of the American Medical Association 244: 2551–2552, 1980

    Article  PubMed  CAS  Google Scholar 

  • Wenting GJ, Derkx FHM, Tan-Tjiong LH, van Seyen AL, Manin’t Veld AJ, et al. Risks of angiotensin converting enzyme inhibition in renal artery stenosis. Kidney International 31: 180–183, 1987

    Google Scholar 

  • Wood SM, Mann RD, Rawlins MD. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. British Medical Journal 294: 91–92, 1987

    Article  PubMed  CAS  Google Scholar 

  • Zachariah PK, Bonnet G, Chrysant SG, DeBacker G, Goldstein R, et al. Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): 53–58, 1987

    Article  Google Scholar 

  • Zanella MT, Mattei Jr E, Draibe SA, Kater CE, Ajzen H. Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure. Clinical Pharmacology and Therapeutics 38: 613–617, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, USA

    Natalie J. Warner & Janet E. Rush

  2. West Point, Pennsylvania, USA

    Natalie J. Warner & Janet E. Rush

Authors
  1. Natalie J. Warner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janet E. Rush
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warner, N.J., Rush, J.E. Safety Profiles of the Angiotensin-Converting Enzyme Inhibitors. Drugs 35 (Suppl 5), 89–97 (1988). https://doi.org/10.2165/00003495-198800355-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198800355-00016

Keywords

Search

Navigation